Autism Biomarkers: Challenges, Pitfalls and Possibilities

Journal of Autism and Developmental Disorders

Volumn 45, Issue 4, 2015, Pages 1103-1113

  Anderson, George M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autism; Biomarker; Conceptualization of autism; Emergenesis; Mutualism; Network

Indexed keywords

BIOLOGICAL MARKER; MELATONIN; OXYTOCIN; SEROTONIN;

AUTISM; GENOTYPE ENVIRONMENT INTERACTION; HEREDITY; HUMAN; IMMUNE SYSTEM; INTELLECTUAL IMPAIRMENT; OXIDATION REDUCTION POTENTIAL; OXIDATIVE STRESS; PLACENTA; PRIORITY JOURNAL; PROTEOMICS; REVIEW; AUTISTIC DISORDER; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; METABOLISM; PHYSIOLOGY; PSYCHOLOGY;

AUTISTIC DISORDER; BIOLOGICAL MARKERS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; HUMANS; OXIDATIVE STRESS; OXYTOCIN; SEROTONIN;

EID: 84925172542     PISSN: 01623257     EISSN: 15733432     Source Type: Journal    
DOI: 10.1007/s10803-014-2225-4     Document Type: Review

References (117)

1. Abyzov, A., Mariani, J., Palejev, D., Zhang, Y., Haney, M. S., Tomasini, L., et al. (2012). Somatic copy number mosaicism in human skin revealed by induced pluripotent stem cells. Nature,492, 438–442.
2. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington, DC: American Psychiatric Publishing.
3. American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.
4. Anagnostou, E., Soorya, L., Brian, J., Dupuis, A., Mankad, D., Smile, S., et al. (2014). Intranasal oxytocin in the treatment of autism spectrum disorders: A review of literature and early safety and efficacy data in youth. Brain Research. doi:10.1016/j.brainres.2014.01.049.
5. Anderson, G. M. (2008). The potential role for emergence in autism. Autism Research, 1, 18–30.
6. Anderson, B. (2001). G as a consequence of shared genes. Intelligence,29, 367–371.
7. Anderson, G. M. (2002). Genetics of childhood disorders: XLV. Autism, Part 4: Serotonin in autism. Journal of the American Academy of Child and & Adolescent Psychiatry,41, 1513–1516.
8. Anderson, G. M. (2009). The role for emergence and submergence in autism. 4th Wales’ International Autism Conference www.awares.org/conferences/show_paper.asp?section=000100010001&conferenceCode= 000200110017&id=249&full_paper=1,2009 (“Autism2009”, on-line conference, keynote paper).
9. Anderson, G. M. (2012). Twin studies in autism: What might they say about genetic and environmental influences. Journal of Autism and Developmental Disorders,42, 1526–1527.
10. Anderson, G. M. (2014). Biochemical biomarkers in autism, chap 19. In Volkmar et al. (Eds.), Handbook of autism and pervasive developmental disorders, 4th edition, pp. 457–481. Hoboken, NJ: Wiley.
11. Anderson, G. M., Cook, E. H, Jr, & Blakely, R. D. (2009). Serotonin rising. New England Journal of Medicine,360, 2580.
12. Anderson, G. M., Hertzig, M. E., & McBride, P. A. (2012). Platelet-poor plasma serotonin in autism. Journal of autism and developmental disorders. Journal of Autism and Developmental Disorders,42, 1510–1514.
13. Anderson, G. M., Horne, W. C., Chatterjee, D., & Cohen, D. J. (1990). The hyperserotonemia of autism. Annals of the New York Academy of Sciences,600, 331–342.
14. Anderson, G. M., Jacobs-Stannard, A., Chawarska, K., Volkmar, F. R., & Kliman, H. J. (2007). Placental trophoblast inclusions in autism spectrum disorder. Biological Psychiatry,61(4), 487–491.
15. Anderson, J. S., Nielsen, J. A., Froehlich, A. L., DuBray, M. B., Druzgal, T. J., Cariello, A. N., et al. (2011). Functional connectivity magnetic resonance imaging classification of autism. Brain,134, 3742–3754.
16. Anderson, G. M., & Stahl, S. S. (2014). Two proposed early biomarker tests of ASD: More harm than good. Journal of Autism and Developmental Disorders,44, 988–989.
17. Baganz, N. L., & Blakely, R. D. (2013). A dialogue between the immune system and brain, spoken in the language of serotonin. ACS Chemical Neuroscience,4, 48–63.
18. Barabási, A. L., Gulbahce, N., & Loscalzo, J. (2011). Network medicine: A network-based approach to human disease. Nature Reviews Genetics,12, 56–68.
19. Bonnin, A., Goeden, N., Chen, K., Wilson, M. L., King, J., Shih, J. C., et al. (2011). A transient placental source of serotonin for the fetal forebrain. Nature,472, 347–350.
20. Bonnin, A., & Levitt, P. (2012). Placental source for 5-HT that tunes fetal brain development. Neuropsychopharmacology,7, 299–300.
21. Borsboom, D. (2008). Psychometric perspectives on diagnostic systems. Journal of Clinical Psychology,64, 1089–1108.
22. Braunschweig, D., Krakowiak, P., Duncanson, P., Boyce, R., Hansen, R. L., Ashwood, P., et al. (2013). Autism-specific maternal autoantibodies recognize critical proteins in developing brain. Translational Psychiatry,3, e277.
23. Bruder, C. E., Piotrowski, A., Gijsbers, A. A., Andersson, R., Erickson, S., Diaz de Ståhl, T., et al. (2008). Phenotypically concordant and discordant monozygotic twins display different DNA copy-number-variation profiles. American Journal of Human Genetics,82, 763–771.
24. Bubenik, G. A. (2002). Gastrointestinal melatonin: Localization, function, and clinical relevance. Digestive Diseases and Sciences,47, 2336–2348.
25. Buchanan, A. V., Weiss, K. M., & Fullerton, S. M. (2006). Dissecting complex disease: The quest for the Philosopher’s Stone? International Journal of Epidemiology,35, 562–571.
26. Bunge, M. (2003). Emergence and convergence: Qualitative novelty and the unity of knowledge. Toronto: University of Toronto Press.
27. Carpentier, P. A., Haditsch, U., Braun, A. E., Cantu, A. V., Moon, H. M., Price, R. O., et al. (2013). Stereotypical alterations in cortical patterning are associated with maternal illness-induced placental dysfunction. The Journal of Neuroscience,33, 16874–16888.
28. Carter, M. T., & Scherer, S. W. (2013). Autism spectrum disorder in the genetics clinic: A review. Clinical Genetics,83, 399–407.
29. Cicchetti, D., & Dawson, G. (2002). Multiple levels of analysis. Development and Psychopathology,14, 417–420.
30. Cicchetti, D., & Toth, S. L. (2009). The past achievements and future promises of developmental psychopathology: The coming of age of a discipline. Journal of Child Psychology and Psychiatry,50, 16–25.
31. Cook, E. H. (1990). Autism: Review of neurochemical investigation. Synapse (New York, NY),6, 292–308.
32. Cramer, A. O., Waldorp, L. J., van der Maas, H. L., & Borsboom, D. (2010a). Comorbidity: A network perspective. Behavioral and Brain Sciences,33, 137–193.
33. Cramer, A. O., Waldorp, L. J., van der Maas, H. L., & Borsboom, D. (2010b). Complex realities require complex theories: Refining and extending the network approach to mental disorders. Behavioral and Brain Sciences,33, 178–193.
34. Cuccaro, M. L., Tuchman, R. F., Hamilton, K. L., Wright, H. H., Abramson, R. K., Haines, J. L., et al. (2012). Exploring the relationship between autism spectrum disorder and epilepsy using latent class cluster analysis. Journal of Autism and Developmental Disorders,42, 1630–1641.
35. Dadds, M. R., MacDonald, E., Cauchi, A., Williams, K., Levy, F., & Brennan, J. (2014). Nasal oxytocin for social deficits in childhood autism: A randomized controlled trial. Journal of Autism and Developmental Disorders,44, 521–531.
36. Dawson, G., Estes, A., Munson, J., Schellenberg, G., Bernier, R., & Abbott, R. (2007). Quantitative assessment of autism symptom-related traits in probands and parents: Broader phenotype autism symptom scale. Journal of Autism and Developmental Disorders,37, 523–536.
37. Dudley, E., Hässler, F., & Thome, J. (2011). Profiling for novel proteomics biomarkers in neurodevelopmental disorders. Expert Review of Proteomics,8, 127–136.
38. Feldman, R., Gordon, I., & Zagoory-Sharon, O. (2011). Maternal and paternal plasma, salivary, and urinary oxytocin and parent-infant synchrony: Considering stress and affiliation components of human bonding. Developmental Science,14, 752–761.
39. Fisher, S. E. (2006). Tangled webs: Tracing the connections between genes and cognition. Cognition,101, 270–279.
40. Flood, Z. C., Engel, D. L., Simon, C. C., Negherbon, K. R., Murphy, L. J., Tamavimok, W., et al. (2012). Brain growth trajectories in mouse strains with central and peripheral serotonin differences: Relevance to autism models. Neuroscience,210, 286–295.
41. Frustaci, A., Neri, M., Cesario, A., Adams, J. B., Domenici, E., Dalla Bernardina, B., et al. (2012). Oxidative stress-related biomarkers in autism: Systematic review and meta-analyses. Free Radical Biology & Medicine,52, 2128–2141.
42. Fukumoto, T., Kema, I. P., & Levin, M. (2005). Serotonin signaling is a very early step in patterning of the left-right axis in chick and frog embryos. Current Biology,15, 794–803.
43. Gabriele, S., Sacco, R., & Persico, A. M. (2014). Blood serotonin levels in autism spectrum disorder: A systematic review and meta-analysis. European Neuropsychopharmacology,24, 919–929.
44. Galano, A., Tan, D. X., & Reiter, R. J. (2011). Melatonin as a natural ally against oxidative stress: A physicochemical examination. Journal of Pineal Research,51, 1–16.
45. Gaugler, T., Klei, L., Sanders, S. J., Bodea, C. A., Goldberg, A. P., Lee, A. B., et al. (2014). Most genetic risk for autism resides with common variation. Nature Genetics,46, 881–885.
46. Gesundheit, B., Rosenzweig, J. P., Naor, D., Lerer, B., Zachor, D. A., Procházka, V., et al. (2013). Immunological and autoimmune considerations of autism spectrum disorders. Journal of Autoimmunity,44, 1–7.
47. Gottlieb, G. (2007). Probabilistic epigenesis. Developmental Science,10, 1–11.
48. Hammock, E. A. (2014). Developmental perspectives on oxytocin and vasopressin. Neuropsychopharmacology. doi:10.1038/npp.2014.120.
49. Happe, F., Ronald, A., & Plomin, R. (2006). Time to give up on a single explanation for autism. Nature Neuroscience,9, 1218–1220.
50. Haque, F. N., Gottesman, I. I. & Wong, A. H. (2009). Not really identical: Epigenetic differences in monozygotic twins and implications for twin studies in psychiatry. American Journal of Medical Genetic C Seminars in Medical Genetics, 15; 151C(2):136–41.
51. Hoge, E. A., Pollack, M. H., Kaufman, R. E., Zak, P. J., & Simon, N. M. (2008). Oxytocin levels in social anxiety disorder. CNS Neuroscience & Therapeutics,14, 165–170.
52. Hu, V. W. (2012). Subphenotype-dependent disease markers for diagnosis and personalized treatment of autism spectrum disorders. Disease Markers,33, 277–288.
53. Insel, T. R. (2010). The challenge of translation in social neuroscience: A review of oxytocin, vasopressin, and affiliative behavior. Neuron,65, 768–779.
54. Jack, A., Connelly, J. J., & Morris, J. P. (2012). DNA methylation of the oxytocin receptor gene predicts neural response to ambiguous social stimuli. Frontiers in Human Neuroscience,6, 280.
55. Jacob, S., Brune, C. W., Carter, C. S., Leventhal, B. L., Lord, C., & Cook, E. H, Jr. (2007). Association of the oxytocin receptor gene (OXTR) in Caucasian children and adolescents with autism. Neuroscience Letters,417, 6–9.
56. Jansen, L. M., Gispen-de Wied, C. C., Wiegant, V. M., Westenberg, H. G., Lahuis, B. E., & van Engeland, H. (2006). Autonomic and neuroendocrine responses to a psychosocial stressor in adults with autistic spectrum disorder. Journal of Autism and Developmental Disorders,36, 891–899.
57. Jones, W., & Klin, A. (2013). Attention to eyes is present but in decline in 2-6-month-old infants later diagnosed with autism. Nature,504, 427–431.
58. Junaid, M. A., Kowal, D., Barua, M., Pullarkat, P. S., Sklower Brooks, S., & Pullarkat, R. K. (2004). Proteomic studies identified a single nucleotide polymorphism in glyoxalase I as autism susceptibility factor. American Journal of Medical Genetics Part A,131, 11–17.
59. Kirsten, T. B., Lippi, L. L., Bevilacqua, E., & Bernardi, M. M. (2013). LPS exposure increases maternal corticosterone levels, causes placental injury and increases IL-1Β levels in adult rat offspring: relevance to autism. PLoS One,8, e82244.
60. Kong, S. W., Collins, C. D., Shimizu-Motohashi, Y., Holm, I. A., Campbell, M. G., Lee, I. H., et al. (2012). Characteristics and predictive value of blood transcriptome signature in males with autism spectrum disorders. PLoS One,7, e49475.
61. Losh, M., & Piven, J. (2007). Social-cognition and the broad autism phenotype: Identifying genetically meaningful phenotypes. Journal of Child Psychology Psychiatry, 48, 105–112.
62. Lyalina, S., Percha, B., LePendu, P., Iyer, S. V., Altman, R. B., & Shah, N. H. (2013). Identifying phenotypic signatures of neuropsychiatric disorders from electronic medical records. Journal of the American Medical Informatics Association, 20, e297–305.
63. Lykken, D. T. (2006). The mechanism of emergenesis. Genes, Brain & Behavior,5, 306–310.
64. Maurer, M. H. (2012). Genomic and proteomic advances in autism research. Electrophoresis,33, 3653–3658.
65. Maxwell, C. R., Parish-Morris, J., Hsin, O., Bush, J. C., & Schultz, R.T. (2013). The broad autism phenotype predicts child functioning in autism spectrum disorders. Journal of Neurodevelopmental Disorders, 5, 25.
66. McBride, P. A., Anderson, G. M., Hertzig, M. E., Snow, M. E., Thompson, S. M., Khait, V. D., et al. (1998). Effects of diagnosis, race, and pubertal status on platelet serotonin levels in autism and mental retardation. Journal of the American Academy of Child and Adolescent Psychiatry,37, 767–779.
67. McBride, P. A., Anderson, G. M., & Shapiro, T. (1996). Autism research. Bringing together approaches to pull apart the disorder. Archives of General Psychiatry,53, 980–983.
68. McNamara, I. M., Borella, A. W., Bialowas, L. A., & Whitaker-Azmitia, P. M. (2008). Further studies in the developmental hyperserotonemia model (DHS) of autism: Social, behavioral and peptide changes. Brain Research,1189, 203–214.
69. Mizejewski, G. J. (2012). Biomarker testing for suspected autism spectrum disorder in early childhood: Is such testing now feasible? Biomark Medicine,6, 503–506.
70. Moss, J., & Howlin, P. (2009). Autism spectrum disorders in genetic syndromes: Implications for diagnosis, intervention and understanding the wider autism spectrum disorder population. Journal of Intellectual Disability Research,53, 852–873.
71. Mulder, E. J., Anderson, G. M., Kema, I. P., de Bildt, A., van Lang, N. D., den Boer, J. A., et al. (2004). Platelet serotonin levels in pervasive developmental disorders and mental retardation: Diagnostic group differences, within-group distribution, and behavioral correlates. Journal of the American Academy of Child and Adolescent Psychiatry,43, 491–499.
72. Nagasawa, M., Kikusui, T., Onaka, T., & Ohta, M. (2009). Dog’s gaze at its owner increases owner’s urinary oxytocin during social interaction. Hormones and Behavior,55, 434–441.
73. Naples, A., Katz, L., & Grigorenko, E. L. (2012). Lexical decision as an endophenotype for reading comprehension: An exploration of an association. Development and Psychopathology,24, 1345–1360.
74. Onore, C., Careaga, M., & Ashwood, P. (2012). The role of immune dysfunction in the pathophysiology of autism. Brain, Behavior, and Immunity,26, 383–392.
75. Parker, K. J., Garner, J. P., Libove, R. A., Hyde, S. A., Hornbeak, K. B., Carson, D. S., Liao, C. P., Phillips, J. M., Hallmayer, J. F., & Hardan AY. (2014). Plasma oxytocin concentrations and OXTR polymorphisms predict social impairments in children with and without autism spectrum disorder. Proceedings of the National Academy of Sciences. 2014 Aug 4. pii: 201402236. [Epub ahead of print].
76. Pierce, K., Conant, D., Hazin, R., Stoner, R., & Desmond, J. (2011). Preference for geometric patterns early in life as a risk factor for autism. Archives of General Psychiatry,68, 101–109.
77. Posey, D. J., Erickson, C. A., & McDougle, C. J. (2008). Developing drugs for core social and communication impairment in autism. Child and Adolescent Psychiatric Clinics of North America,17, 787–801.
78. Preti, A., Melis, M., Siddi, S., Vellante, M., Doneddu, G., & Fadda, R. (2004). Oxytocin and autism: A systematic review of randomized controlled trials. Journal of Child and Adolescent Psychopharmacology,24, 54–68.
79. Purcell, A. E., Jeon, O. H., Zimmerman, A. W., Blue, M. E., & Pevsner, J. (2001). Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology,57, 1618–1628.
80. Ratajczak, H. V. (2011). Theoretical aspects of autism: Biomarkers–a review. Journal of Immunotoxicology,8, 80–94.
81. Reiter, R. J., Tan, D. X., Tamura, H., Cruz, M. H., & Fuentes-Broto, L. (2014). Clinical relevance of melatonin in ovarian and placental physiology: A review. Gynecological Endocrinology,30, 83–89.
82. Richters, J. E. (1997). The Hubble hypothesis and the developmentalist’s dilemma. Deveploment and Psychopathol,9, 193–199.
83. Ross, H. E., & Young, L. J. (2009). Oxytocin and the neural mechanisms regulating social cognition and affiliative behavior. Frontiers in Neuroendocrinology,30, 534–547.
84. Rossi, J., Newschaffer, C., & Yudell, M. (2013). Autism spectrum disorders, risk communication, and the problem of inadvertent harm. Kennedy Institute of Ethics Journal,23, 105–138.
85. Rossignol, D. A., & Frye, R. E. (2011). Melatonin in autism spectrum disorders: A systematic review and meta-analysis. Developmental Medicine and Child Neurology,53, 783–792.
86. Ruggeri, B., Sarkans, U., Schumann, G., & Persico, A. M. (2014). Biomarkers in autism spectrum disorder: The old and the new. Psychopharmacology (Berl),231, 1201–1216.
87. Rutter, M. L. (2011). Progress in understanding autism: 2007–2010. Journal of Autism and Developmental Disorders,41, 395–404.
88. Rutter, M. L. (2014). Genetics of autism spectrum disorders. in Handbook of Autism and Pervasive Developmental Disorders, 4th edition, Volkmar et al. eds., J. Wiley & Sons, Hoboken, NJ.
89. Salafia, C. M, Platt, C, Girardi, T, Shah, R, Merz, G., & Misra, D. P. (2014). Placental structure in ASD: Does the placenta mirror the diagnosis? Abstract # 17578, 2014 International Meeting for Autism Research, Atlanta, GA, May 14–17, 2014.
90. Scahill, L., & Anderson, G. M. (2010). Is ecstasy an empathogen? Biological Psychiatry,68, 1082–1083.
91. Schain, R. J., Freedman, D. X. (1961). Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. Journal of Pediatrics,58, 315–320.
92. Skuse, D. H. (2007). Rethinking the nature of genetic vulnerability to autistic spectrum disorders. Trends in Genetics,23, 387–395.
93. Skuse, D. H., Gallagher, L. (2011). Genetic influences on social cognition. Pediatric Research,69(5 Pt 2), 85R–91R.
94. Spencer, J. P., Perone, S., Buss, A. T. (2011). Twenty years and going strong: A dynamic systems revolution in motor and cognitive development. Child Development Perspectives,5, 260–266.
95. Srivastava, A. K., Schwartz, C. E. (2014). Intellectual disability and autism spectrum disorders: Causal genes and molecular mechanisms. Neuroscience and Biobehavioral Reviews. doi:10.1016/j.neubiorev.2014.02.015.
96. Stromswold, K. (2006). Why aren’t identical twins linguistically identical? Cognition,101, 333–384.
97. Sucksmith, E., Roth, I., & Hoekstra, R. A. (2011). Autistic traits below the clinical threshold: Re-examining the broader autism phenotype in the 21st century. Neuropsychology Review, 21, 360–389.
98. Tordjman, S., Najjar, I., Bellissant, E., Anderson, G. M., Barburoth, M., Cohen, D., et al. (2013). Advances in the research of melatonin in autism spectrum disorders: Literature review and new perspectives. International Journal of Molecular Sciences,14, 20508–20542.
99. van der Maas, H. L., Dolan, C. V., Grasman, R. P., Wicherts, J. M., Huizenga, H. M., Raijmakers, M. E. (2006). A dynamical model of general intelligence: The positive manifold of intelligence by mutualism. Psychological Review,113, 842–861.
100. van Praag, H. M. (2003). Itinerary: Concerning the professional and spiritual objectives of my life. Medical Humanities,29, 89–96.
101. Veenstra-VanderWeele, J., Blakely, R. D. (2012). Networking in autism: Leveraging genetic, biomarker and model system findings in the search for new treatments. Neuropsychopharmacology,37, 196–212.
102. Veenstra-VanderWeele, J., Muller, C. L., Iwamoto, H., Sauer, J. E., Owens, W. A., Shah, C. R., et al. (2012). Autism gene variant causes hyperserotonemia, serotonin receptor hypersensitivity, social impairment and repetitive behavior. Proceedings of the National Academy of Sciences USA,109, 5469–5474.
103. Velasquez, J. C., Goeden, N., & Bonnin, A. (2013). Placental serotonin: Implications for the developmental effects of SSRIs and maternal depression. Frontiers in Cellular Neuroscience,7, 47.
104. Villagonzalo, K. A., Dodd, S., Dean, O., Gray, K., Tonge, B., & Berk, M. (2010). Oxidative pathways as a drug target for the treatment of autism. Expert Opinion on Therapeutic Targets,14, 1301–1310.
105. Voineagu, I. (2012). Gene expression studies in autism: Moving from the genome to the transcriptome and beyond. Neurobiology of Disease,45, 69–75.
106. Volkmar, F. R., Reichow, B., Westphal, A., & Mandell, D.S. (2014). Autism and the autism spectrum: Diagnostic concepts, chap 1, pp. 3–27, in Handbook of Autism and Pervasive Developmental Disorders, 4th edition, ed. by Volkmar et al, J. Wiley & Sons, Hoboken, NJ.
107. Wald, N. J., Hackshaw, A. K., & Frost, C. D. (1999). When can a risk factor be used as a worthwhile screening test?. BMJ,319(7224), 1562–1565.
108. Walker, C. K., Anderson, K. W., Milano, K. M., Ye, S., Tancredi, D. J., & Pessah I. N., et al. (2013). Hertz-Picciotto I, Kliman HJ. Trophoblast inclusions are significantly increased in the placentas of children in families at risk for autism. Biol Psychiatry, 74, 204–11.
109. Walsh, P., Elsabbagh, M., Bolton, P., & Singh, I. (2011). In search of biomarkers for autism: Scientific, social and ethical challenges. Nature Reviews Neuroscience,12, 603–612.
110. Wang, L., Angley, M. T., Gerber, J. P., & Sorich, M. J. (2011). A review of candidate urinary biomarkers for autism spectrum disorder. Biomarkers,16, 537–552.
111. Wang, H., Chen, C., & Fushing, H. (2012). Extracting multiscale pattern information of fMRI based functional brain connectivity with application on classification of autism spectrum disorders. PLoS One,7, e45502.
112. Wing, L., & Wing, J. K. (1971). Multiple impairments in early childhood autism. Journal of Autism & Childhood Schizophrenia,1, 256–266.
113. Yerys, B. E., & Pennington, B. F. (2011). How do we establish a biological marker for a behaviorally defined disorder? Autism as a test case. Autism Research,4, 239–241.
114. Yordanova, J., Kolev, V., Kirov, R., & Rothenberger, A. (2010). Comorbidity in the context of neural network properties. Behavioral and Brain Sciences,33, 176–177.
115. Young, J. G., Kavanagh, M. E., Anderson, G. M., Shaywitz, B. A., & Cohen, D. J. (1982). Clinical neurochemistry of autism and associated disorders. Journal of Autism and Developmental Disorders,12, 147–165.
116. Young, S. N., Moskowitz, D. S., & aan het Rot, M. (2014). Possible role of more positive social behaviour in the clinical effect of antidepressant drugs. Journal of Psychiatry and Neuroscience,39, 60–65.
117. Yuwiler, A., Geller, A., & Ritvo, E. (1985). Biochemical studies of autism. In E. Lajtha (Ed.), Handbook of neurochemistry (pp. 671–691). New York: Plenum.